Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

Conditions

• Non-alcoholic Steatohepatitis

Interventions

• DRUG: TQA2225/AP025 or TQA2225/AP025 Placebo 25mg
• DRUG: TQA2225/AP025 or TQA2225/AP025 Placebo 50mg

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.